You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Daptomycin is active against gram-positive bacteria only. In mixed infections where gram-negative and/or certain types of anaerobic bacteria are suspected, Daptomycin GH should be co-administered with appropriate antibacterial agent(s).,Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Daptomycin GH is not indicated for the treatment of pneumonia.,Adult Patients (greater than or equal to 18 years of age),Complicated Skin and Skin Structure Infections,Daptomycin GH is indicated for the treatment of adults (greater than or equal to 18 years of age) with complicated skin and skin structure infections (cSSSI) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,Staphylococcus aureus Bloodstream Infections (Bacteraemia),Daptomycin GH is indicated in adults (greater than or equal to 18 years of age) for Staphylococcus aureus bloodstream infections (bacteraemia), including right-sided native valve infective endocarditis (RIE), caused by methicillin-susceptible and methicillin-resistant isolates.,The efficacy of daptomycin in patients with prosthetic heart valves or in left-sided endocarditis due to S. aureus has not been demonstrated. In the setting of S. aureus bacteraemia (SAB), if a focus of infection is diagnosed as left-sided endocarditis after Daptomycin GH therapy has been initiated, then consideration should be given to instituting alternative antibacterial therapy (see Section 4.4 Special Warnings and Precautions for Use).,Paediatric patients (1 to 17 years of age),Daptomycin GH is not indicated for treatment of patients less than 1 year of age (see Section 4.4 Special Warnings and Precautions for Use - Paediatric Use). Daptomycin GH has not been studied in treatment of infective endocarditis in children (see Section 5.1 Pharmacodynamic Properties - Clinical Trials and Section 4.4 Special Warnings and Precautions for Use).,Complicated Skin and Skin Structure Infections,Daptomcyin GH is indicated for the treatment of patients aged 1 to 17 years with complicated skin and skin structure infections (cSSSI) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,S. aureus Bloodstream Infections (Bacteraemia),Daptomycin GH is indicated in paediatric patients (1 to 17 years of age) with SAB not due to pneumonia, caused by daptomycin-susceptible isolates. Empiric treatment should be reviewed based on the results of susceptibility testing. Prescribing should be in accordance with nationally or locally-endorsed guidelines for the treatment of SAB.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Daptomycin is active against gram-positive bacteria only. In mixed infections where gram-negative and/or certain types of anaerobic bacteria are suspected, Daptomycin GH should be co-administered with appropriate antibacterial agent(s).,Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Daptomycin GH is not indicated for the treatment of pneumonia.,Adult Patients (greater than or equal to 18 years of age),Complicated Skin and Skin Structure Infections,Daptomycin GH is indicated for the treatment of adults (greater than or equal to 18 years of age) with complicated skin and skin structure infections (cSSSI) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,Staphylococcus aureus Bloodstream Infections (Bacteraemia),Daptomycin GH is indicated in adults (greater than or equal to 18 years of age) for Staphylococcus aureus bloodstream infections (bacteraemia), including right-sided native valve infective endocarditis (RIE), caused by methicillin-susceptible and methicillin-resistant isolates.,The efficacy of daptomycin in patients with prosthetic heart valves or in left-sided endocarditis due to S. aureus has not been demonstrated. In the setting of S. aureus bacteraemia (SAB), if a focus of infection is diagnosed as left-sided endocarditis after Daptomycin GH therapy has been initiated, then consideration should be given to instituting alternative antibacterial therapy (see Section 4.4 Special Warnings and Precautions for Use).,Paediatric patients (1 to 17 years of age),Daptomycin GH is not indicated for treatment of patients less than 1 year of age (see Section 4.4 Special Warnings and Precautions for Use - Paediatric Use). Daptomycin GH has not been studied in treatment of infective endocarditis in children (see Section 5.1 Pharmacodynamic Properties - Clinical Trials and Section 4.4 Special Warnings and Precautions for Use).,Complicated Skin and Skin Structure Infections,Daptomcyin GH is indicated for the treatment of patients aged 1 to 17 years with complicated skin and skin structure infections (cSSSI) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,S. aureus Bloodstream Infections (Bacteraemia),Daptomycin GH is indicated in paediatric patients (1 to 17 years of age) with SAB not due to pneumonia, caused by daptomycin-susceptible isolates. Empiric treatment should be reviewed based on the results of susceptibility testing. Prescribing should be in accordance with nationally or locally-endorsed guidelines for the treatment of SAB.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Daptomycin is active against gram-positive bacteria only. In mixed infections where gram-negative and/or certain types of anaerobic bacteria are suspected, Daptomycin GH should be co-administered with appropriate antibacterial agent(s).,Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Daptomycin GH is not indicated for the treatment of pneumonia.,Adult Patients (greater than or equal to 18 years of age),Complicated Skin and Skin Structure Infections,Daptomycin GH is indicated for the treatment of adults (greater than or equal to 18 years of age) with complicated skin and skin structure infections (cSSSI) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,Staphylococcus aureus Bloodstream Infections (Bacteraemia),Daptomycin GH is indicated in adults (greater than or equal to 18 years of age) for Staphylococcus aureus bloodstream infections (bacteraemia), including right-sided native valve infective endocarditis (RIE), caused by methicillin-susceptible and methicillin-resistant isolates.,The efficacy of daptomycin in patients with prosthetic heart valves or in left-sided endocarditis due to S. aureus has not been demonstrated. In the setting of S. aureus bacteraemia (SAB), if a focus of infection is diagnosed as left-sided endocarditis after Daptomycin GH therapy has been initiated, then consideration should be given to instituting alternative antibacterial therapy (see Section 4.4 Special Warnings and Precautions for Use).,Paediatric patients (1 to 17 years of age),Daptomycin GH is not indicated for treatment of patients less than 1 year of age (see Section 4.4 Special Warnings and Precautions for Use - Paediatric Use). Daptomycin GH has not been studied in treatment of infective endocarditis in children (see Section 5.1 Pharmacodynamic Properties - Clinical Trials and Section 4.4 Special Warnings and Precautions for Use).,Complicated Skin and Skin Structure Infections,Daptomcyin GH is indicated for the treatment of patients aged 1 to 17 years with complicated skin and skin structure infections (cSSSI) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,S. aureus Bloodstream Infections (Bacteraemia),Daptomycin GH is indicated in paediatric patients (1 to 17 years of age) with SAB not due to pneumonia, caused by daptomycin-susceptible isolates. Empiric treatment should be reviewed based on the results of susceptibility testing. Prescribing should be in accordance with nationally or locally-endorsed guidelines for the treatment of SAB.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Daptomycin is active against gram-positive bacteria only. In mixed infections where gram-negative and/or certain types of anaerobic bacteria are suspected, Daptomycin GH should be co-administered with appropriate antibacterial agent(s).,Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Daptomycin GH is not indicated for the treatment of pneumonia.,Adult Patients (greater than or equal to 18 years of age),Complicated Skin and Skin Structure Infections,Daptomycin GH is indicated for the treatment of adults (greater than or equal to 18 years of age) with complicated skin and skin structure infections (cSSSI) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,Staphylococcus aureus Bloodstream Infections (Bacteraemia),Daptomycin GH is indicated in adults (greater than or equal to 18 years of age) for Staphylococcus aureus bloodstream infections (bacteraemia), including right-sided native valve infective endocarditis (RIE), caused by methicillin-susceptible and methicillin-resistant isolates.,The efficacy of daptomycin in patients with prosthetic heart valves or in left-sided endocarditis due to S. aureus has not been demonstrated. In the setting of S. aureus bacteraemia (SAB), if a focus of infection is diagnosed as left-sided endocarditis after Daptomycin GH therapy has been initiated, then consideration should be given to instituting alternative antibacterial therapy (see Section 4.4 Special Warnings and Precautions for Use).,Paediatric patients (1 to 17 years of age),Daptomycin GH is not indicated for treatment of patients less than 1 year of age (see Section 4.4 Special Warnings and Precautions for Use - Paediatric Use). Daptomycin GH has not been studied in treatment of infective endocarditis in children (see Section 5.1 Pharmacodynamic Properties - Clinical Trials and Section 4.4 Special Warnings and Precautions for Use).,Complicated Skin and Skin Structure Infections,Daptomcyin GH is indicated for the treatment of patients aged 1 to 17 years with complicated skin and skin structure infections (cSSSI) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,S. aureus Bloodstream Infections (Bacteraemia),Daptomycin GH is indicated in paediatric patients (1 to 17 years of age) with SAB not due to pneumonia, caused by daptomycin-susceptible isolates. Empiric treatment should be reviewed based on the results of susceptibility testing. Prescribing should be in accordance with nationally or locally-endorsed guidelines for the treatment of SAB.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
